Medicines Co. (MDCO) Reports Q4 Loss of $0.61, Miss on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Medicines Co. (MDCO) Reports Q4 Loss of $0.61, Miss on Revenues

Medicines Co. (MDCO) Reports Completed Enrollment Target Ahead of Schedule for ORION-9 Phase 3 Trial

February 20, 2018 7:16 AM EST

The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks considerably ahead of its anticipated recruitment goal of 24 weeks.

ORION-9 is a double-blind, randomized multi-national Phase III trial designed to confirm the effectiveness and safety of inclisiran in heterozygous familial hypercholesterolemia patients. In the trial, patients are randomized to inclisiran 300 mg or placebo given subcutaneously on days 1, 90, 270 and 450 then followed to the end of the study at 540 days (18 months). ORION-9 is one of four pivotal phase III trials with similar designs... More